Senexin C
CAS No. 2375554-02-0
Senexin C ( —— )
产品货号. M35662 CAS No. 2375554-02-0
Senexin C 是一种选择性和具有口服活性的 CDK8/19 抑制剂。Senexin C 显示出强烈的肿瘤富集药代动力学 (PK) 谱和肿瘤药效学 (PD) 标志物反应。Senexin C 抑制 MV4-11 白血病细胞的生长具有良好的耐受性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥4551 | 有现货 |
|
| 10MG | ¥6479 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥4513 | 有现货 |
|
生物学信息
-
产品名称Senexin C
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Senexin C 是一种选择性和具有口服活性的 CDK8/19 抑制剂。Senexin C 显示出强烈的肿瘤富集药代动力学 (PK) 谱和肿瘤药效学 (PD) 标志物反应。Senexin C 抑制 MV4-11 白血病细胞的生长具有良好的耐受性。
-
产品描述Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability.
-
体外实验Senexin C (compound 20a) exhibits potent CDK8/19 inhibitory activity with high selectivity (IC50s of 56 and 108 nM for 293-NFκB-Luc and MV4-11-Luc cells, respectively).Senexin C (2 μM) shows potency in different kinase assays (IC50= 3.6 nM for CD8/CycC, Kd=1.4 nM for CD8/CycC, Kd=2.9 nM for CDK19/CycC).Senexin C (1 μM, 3 h) shows inhibition on CDK8/19 dependent cellular gene expression.RT-PCR Cell Line:293 cells Concentration:1 μM Incubation Time:3 h Result:Showed inhibition on CDK8/19 dependent cellular gene expression.
-
体内实验Senexin C (2.5 mg/kg, i.v.; 100 mg/kg, p.o.) shows good oral bioavailability.Senexin C (40 mg/kg; p.o.; twice daily for 4 weeks) suppresses the systemic growth of MV4-11 AML with good tolerability.Pharmacokinetic Parameters of Senexin C in eight-week-old female Balb/c mice.Eight-week-old female Balb/c mice ( CT26 tumor mode), 2.5 mg/kg, i.v.(2.5 mg/mL Senexin C solution in 5% dextrose); 100 mg/kg, p.o.(10 mg/mL Senexin C solution in 30% propylene glycol/70% PEG-400 vehicle).Animal Model:eight-week-old female Balb/c mice ( CT26 tumor mode)Dosage:2.5 mg/kg (10 mL/kg of 2.5 mg/mL Senexin C solution in 5% dextrose), 100 mg/kg (10 mL/kg of 10 mg/mL Senexin C solution in 30% propylene glycol/70% PEG-400 vehicle) Administration:2.5 mg/kg, i.v.; 100 mg/kg, p.o.Result:Showed good oral bioavailability.Animal Model:eight-week-old female NSG mice ( AML model) Dosage:40 mg/kg Administration:p.o.; twice daily, 4 weeks Result:Suppressed the systemic growth of MV4-11 AML with good tolerability.
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点CDK
-
受体CDK
-
研究领域——
-
适应症——
化学信息
-
CAS Number2375554-02-0
-
分子量449.55
-
分子式C28H27N5O
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 33.33 mg/mL (74.14 mM; ultrasonic and warming and heat to 160°C)
-
SMILESN#CC=1C=CC2=NC=CC(NCCC=3C=CC4=CC(=CC=C4C3)C(=O)N5CCN(C)CC5)=C2C1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zhang L, et al. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022; 65(4):3420-3433.?
产品手册
关联产品
-
Roscovitine
一种有效的选择性 CDK 抑制剂,对 CDK5、Cdc2 和 CDK2 的 IC50 值分别为 0.2 uM、0.65 uM 和 0.7 uM。
-
(R)-Enitociclib
(R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.
-
AT-7519 trifluoroace...
一种有效的 CDK2 抑制剂,IC50 为 47 nM;还抑制 CDK1/4/5,IC50 为 190/67/18 nM,并对某些激酶(Aurora A、IR 激酶、MEK、PDK1、c-Abl,IC50>10 uM)表现出选择性。
021-51111890
购物车()
sales@molnova.cn

